Moderna provides updates on mRNA vaccine platform

By The Science Advisory Board staff writers

April 14, 2021 -- Moderna gave updates on its messenger RNA (mRNA) vaccines during its second annual Vaccines Day event. The company plans to continue to invest resources to accelerate the development of its mRNA vaccine platforms.

In addition to highlighting the advantages of these types of vaccines, the company announced that its seven-month data for its cytomegalovirus (CMV) vaccine candidate show that all its measures of neutralizing antibody geometric mean titers (GMTs) are at or above CMV seropositive baselines. A phase III study will evaluate the vaccine in about 8,000 participants in 2021.

Also, interim analysis of a phase I vaccine candidate (mRNA-1345) for respiratory syncytial virus (RSV) shows a greater than elevenfold increase in RSV-neutralizing antibodies in individuals between the ages of 18 and 49. Participants tolerated 50-µg and 100-µg dose levels well.

Lastly, Moderna plans to begin a phase I study evaluating HIV mRNA vaccine candidates, as well as a phase I clinical study of an mRNA flu vaccine candidate in 2021. To date, the company has started clinical trials for 14 different mRNA vaccine candidates.

Moderna highlights 6-month antibody persistence of its COVID-19 vaccine
Antibody persistence lasted through six months following the second dose of Moderna's COVID-19 vaccine, according to a study published April 6 in the...
Moderna announces administration of pediatric COVID-19 vaccine doses
Moderna announced that the first participants have been dosed in its phase II/III study of its pediatric messenger RNA (mRNA) COVID-19 vaccine candidate,...
Moderna doses 1st patients in COVID-19 vaccine booster trial
Moderna has dosed the first patients in its study of modified COVID-19 vaccines, designed to address the potential need for vaccine booster candidates.
Baxter BioPharma to provide fill/finish services for Moderna vaccine
Baxter BioPharma has entered into an agreement with Moderna to provide fill/finish sterile manufacturing services and supply packaging for approximately...
Moderna addresses SARS-CoV-2 variants, ramps up vaccine production
Moderna is pursuing two strategies against emerging SARS-CoV-2 variants. The company is evaluating booster vaccine doses and is increasing vaccine manufacturing...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter